Health Dictionary Find a Doctor

Altered mental status

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]


Overview

An altered level of consciousness is any measure of arousal other than normal. Level of consciousness (LOC) is a measurement of a person’s arousability and responsiveness to stimuli from the environment. A mildly depressed level of consciousness or alertness may be classed as lethargy; someone in this state can be aroused with little difficulty. People who are obtunded have a more depressed level of consciousness and cannot be fully aroused. Those who are not able to be aroused from a sleep-like state are said to be stuporous. Coma is the inability to make any purposeful response. Scales such as the Glasgow coma scale have been designed to measure the level of stuporconsciousness.

An altered level of consciousness can result from a variety of factors, including alterations in the chemical environment of the brain (e.g. exposure to poisons or intoxicants), insufficient oxygen or blood flow in the brain, and excessive pressure within the skull. Level of consciousness may decline abruptly or slowly, or it may increase and decrease intermittently. Prolonged unconsciousness is understood to be a sign of a medical emergency. A deficit in the level of consciousness suggests that both of the cerebral hemispheres or the reticular activating system have been injured. A decreased level of consciousness correlates to increased morbidity (disability) and mortality (death). Thus it is a valuable measure of a patient’s medical and neurological status. In fact, some sources consider level of consciousness to be one of the vital sign.[1]

Core Concepts

  • Altered mental status: Altered mental status is a collection of states with change in cognitive contain, vigilance, and attentiveness.
  • Cognition: Cognition is a cortical function in which knowledge is gained by ones reasoning, or without the need for conscious reasoning (instincts) and perceptions.
  • Vigilance: Vigilance is a calibration of awakeness. Vigilance is low in sleep and is higher person is awake.
  • Mental content:Mental content is a capacity of a person to integrate past and present experiences to the stimuli to the external and internal world.
  • Attention: Attention is an ability to choose and concentrate a stimuli from all mental content which is relevant to a given situation.[2]

Glasgow Coma Scale

Glasgow Coma Scale
1 2 3 4 5 6
Eye Does not open eyes Opens eyes in response to painful stimuli Opens eyes in response to voice Opens eyes spontaneously N/A N/A
Verbal Makes no sounds Incomprehensible sounds Utters inappropriate words Confused, disoriented Oriented, converses normally N/A
Motor Makes no movements Extension to painful stimuli (decerebrate response) Abnormal flexion to painful stimuli (decorticate response) Flexion / Withdrawal to painful stimuli Localizes painful stimuli Obeys commands

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo, M.D., Pratik Bahekar, MBBS [2]

Overview

The description of altered mental status might have been employed as early as 30,000 years ago. Celsus was the first person to use the word delirium, adapted from phrenitis, the description of alteration in consciousness by Hippocrates. Procopius gave a detailed description of what now is known as hypoactive and hyperactive delirium. Altered mental status was poorly understood before 19th century and was merely seen as symptoms of intoxication or demonic possession. A chronic global ischaemia hypothesis due to atherosclerosis was suggested to be the causant all cognitive alterations, including psychiatric disorders, such as schizophrenia. New investigations are being developed to understand the neural and psychological mechanisms of consciousness, such as priming effects using subliminal stimuli, alterations in consciousness produced by trauma, illness, or drugs.

Discovery

  • The description of altered mental status might have been employed as early as 30,000 years ago, many times called “mystic state“.[1]
  • Celsus was the first person to use the word delirium (second century AD) to refer to a mental disorder that appeared after a head trauma or during fever;[2] he then equally used the term phrenitis introduced by Hippocrates (500 BC) as a synonym of delirium.[3]
  • In year 542 AD, Procopius gave a detailed description of delirium either as violent with insomnia, excitement, shouting, and rushing off in flight (now hyperactive delirium) or drifted into coma, forgetting all those familiar to them (now hypoactive delirium).[2]
  • Acoording to data, “Conscious” and “consciousness” was first mentioned in English language back in 16th century; it is derived from the Latin (con- “together” +scio “to know”).[4]
  • Before the 18th century, dementia was called imbecility, morosis, fatuitas, anoea, foolishness, stupidity, simplicity, carus, idiocy, dotage, or senility, which was used to refer to the varying degree of behavioural deterioration.[5]
  • The modern concept of consciousness is attributed to the English physician and phylosopher John Locke, who published in 1690 his essay “Concerning Human Understanding”.[6] Locke defined consciousness as “the perception of what passes in a man’s own mind“.[1]
  • The word dementia was introduced by Blancard in 1726 to refer to the extinction of the imagination and judgment;[7] in 1765, the word was updated by Diderot as the abolition of the reasoning faculty.[8]

Landmark Events in the Development of Treatment Strategies

  • At the begining of the nineteenth century, studies like those from Rostan in 1823 atributed cognitive failure to softening of the brain, which was observed by post-mortem findings in old people who presented dementia features in life.[7]
  • In the 20th century, studies like those from North and Bostock in1925, found atherosclerotic changes in autopsies of many of the patients with dementia, which suggested for many years a ‘chronic global ischaemia’ hypothesis where all cognitive alterations were due to atherosclerosis, including disorders such as schizophrenia.[9]
  • New investigations are being developed to understand the neural and psychological mechanisms of consciousness, such as priming effects using subliminal stimuli, alterations in consciousness produced by trauma, illness, or drugs.

Impact on Cultural History

Famous Cases

  • The creativity and the work of famous paintings such as “The Starry Night” from Vincent van Gogh is well known to be influenced in someway by alterations in mental status; it is still not completly known if it may be due to the effects of absinthe, overmedication with digitalis, epilepsy or a manic depression.[11]

References

  1. 1.0 1.1 “Science & Technology: consciousness”. Encyclopædia Britannica. Retrieved August 20, 2010.
  2. 2.0 2.1 Adamis, Dimitrios; Treloar, Adrian; Martin, Finbarr C.; Macdonald, Alastair J.D. (2016). “A brief review of the history of delirium as a mental disorder”. History of Psychiatry. 18 (4): 459–469. doi:10.1177/0957154X07076467. ISSN 0957-154X.
  3. Cruz-Coke R (May 1999). “[Hippocratic philosophy]”. Rev Med Chil (in Spanish; Castilian). 127 (5): 611–4. PMID 10451633.
  4. {{cite book |title=Studies in words |author =[[C. S. Lewis|year=1990 |publisher=Cambridge University Press |chapter=Ch. 8: Conscience and conscious |isbn=978-0-521-39831-2}}
  5. Berrios, G. E. (1994). “Dementia: Historical Overview”: 5–19. doi:10.1007/978-1-4615-6805-6_1.
  6. Locke, John. “An Essay Concerning Human Understanding (Chapter XXVII)”. Australia: University of Adelaide. Retrieved August 20, 2010.
  7. 7.0 7.1 Nägga, A. K.; Marcusson, J. (2014). “Associated physical disease in a demented population”. Aging Clinical and Experimental Research. 10 (6): 440–444. doi:10.1007/BF03340156. ISSN 1594-0667.
  8. “Evolución histórica de la enciclopedia: Diderot y la enciclopedia francesa. Biblioteca Nacional de España”.
  9. Berrios, G. E. (1990). “Alzheimer’s disease: A conceptual history”. International Journal of Geriatric Psychiatry. 5 (6): 355–365. doi:10.1002/gps.930050603. ISSN 0885-6230.
  10. “ndl.ethernet.edu.et” (PDF).
  11. Wolf P (November 2001). “Creativity and chronic disease. Vincent van Gogh (1853-1890)”. West J Med. 175 (5): 348. doi:10.1136/ewjm.175.5.348. PMC 1071623. PMID 11694494.

Template:WikiDoc Sources

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo, M.D., Pratik Bahekar, MBBS [2]

Overview

Altered mental status, despite its frequency, the term is vague and has several synonyms such as confusion, not acting right, confusional state, altered behavior, generalized weakness, lethargy, agitation, psychosis, disorientation, inappropriate behavior, inattention, and hallucination. Such lack of standardized terminology makes the assessment and appropriate management of patients with altered mental status difficult. It is important to ditinguish red flags, since acute altered mental status is a medical emergency. The first step in the evaluation of a patient with altered mental status is to establish the time course. Altered mental status may be classified as dementia, delirium, psychosis, and other neurological causes according to its origin.

Classification

Dementia

Delirium

Psychosis

Neurologic causes


References

  1. Buffington AL, Lipski DM, Westfall E (October 2013). “Dementia: an evidence-based review of common presentations and family-based interventions”. J Am Osteopath Assoc. 113 (10): 768–75. doi:10.7556/jaoa.2013.046. PMID 24084803.
  2. Reitz C, Mayeux R (April 2014). “Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers”. Biochem Pharmacol. 88 (4): 640–51. doi:10.1016/j.bcp.2013.12.024. PMC 3992261. PMID 24398425.
  3. Boltey EM, Iwashyna TJ, Hyzy RC, Watson SR, Ross C, Costa DK (June 2019). “Ability to predict team members’ behaviors in ICU teams is associated with routine ABCDE implementation”. J Crit Care. 51: 192–197. doi:10.1016/j.jcrc.2019.02.028. PMC 6625516 Check |pmc= value (help). PMID 30856524.
  4. Airagnes G, Ducoutumany G, Laffy-Beaufils B, Le Faou AL, Limosin F (June 2019). “Alcohol withdrawal syndrome management: Is there anything new?”. Rev Med Interne. 40 (6): 373–379. doi:10.1016/j.revmed.2019.02.001. PMID 30853380.
  5. Michels M, Michelon C, Damásio D, Vitali AM, Ritter C, Dal-Pizzol F (May 2019). “Biomarker Predictors of Delirium in Acutely Ill Patients: A Systematic Review”. J Geriatr Psychiatry Neurol. 32 (3): 119–136. doi:10.1177/0891988719834346. PMID 30852930.
  6. van Os J, Hanssen M, Bijl RV, Vollebergh W (July 2001). “Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison”. Arch Gen Psychiatry. 58 (7): 663–8. doi:10.1001/archpsyc.58.7.663. PMID 11448373.
  7. Jellinger KA (May 2012). “Cerebral correlates of psychotic syndromes in neurodegenerative diseases”. J Cell Mol Med. 16 (5): 995–1012. doi:10.1111/j.1582-4934.2011.01311.x. PMC 4365880. PMID 21418522.
  8. Fiorentini A, Volonteri LS, Dragogna F, Rovera C, Maffini M, Mauri MC, Altamura CA (December 2011). “Substance-induced psychoses: a critical review of the literature”. Curr Drug Abuse Rev. 4 (4): 228–40. doi:10.2174/1874473711104040228. PMID 21999698.
  9. Grover S, Kate N (August 2012). “Assessment scales for delirium: A review”. World J Psychiatry. 2 (4): 58–70. doi:10.5498/wjp.v2.i4.58. PMC 3782167. PMID 24175169.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo, M.D., Pratik Bahekar, MBBS [2]

Overview

Altered mental status is a state of a variety of diseases, hence, there is no single pathophysiology mechanism. Although, the neural science behind alertness, wakefulness, and arousal are not fully understood, it is known that the reticular formation plays an important role in these.

Pathogenesis

Altered mental status is a state of a variety of diseases, hence, there is no single pathophysiology mechanism. It is known that the reticular formation plays an important role in the state of alertness. We explain the most important subtypes of altered mental status:

Dementia

Alzheimer’s disease

While the pathogenesis of AD remains unclear, It is thought that dementia is the result of:

Parkinson’s disease

The pathogenesis of Parkinson’s disease is a depletion of dopamine due to the following mechanisms:

Delirium

Delirium is caused by a broad spectrum of diseases and clinical problems. Among the hypothesis of delirium developement are:

Genetics

Dementia

Alzheimer’s disease

Early onset (Alzheimer’s dementia-AD 1, 3 and 4)

30-50 percent of early-onset Alzheimer’s dementia (AD) is associated with an autosomal dominant inheritance and consists of mutations in the following genes:[32][33]

Late onset (Alzheimer’s dementia -AD2)

Parkinson’s disease

Some of specific genes involving in PD are:

Delirium

The genes that may be used as risk biomarkers for the developement of delirium are the following:

Associated Conditions

The most important conditions/diseases associated with altered mental status include:

Gross Pathology

Dementia

Alzheimer’s disease

The most important characteristics of Alzheimer’s disease on gross pathology are:

Parkinson’s disease

The most important characteristics of Parkinson’s disease on gross pathology are:

Delirium

There are no characteristic gross pathology findings in dementia.

Microscopic Pathology

Dementia

Alzheimer’s disease

The most important histopathological characteristics of Alzheimer’s disease are:

Parkinson’s disease

The most important histopathological characteristics of Parkinson’s disease are:

Delirium

There are no characteristic histopathological findings in delirium.

References

  1. Beach TG, Walker R, McGeer EG (1989). “Patterns of gliosis in Alzheimer’s disease and aging cerebrum”. Glia. 2 (6): 420–36. doi:10.1002/glia.440020605. PMID 2531723.
  2. DeKosky ST, Scheff SW (1990). “Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity”. Ann. Neurol. 27 (5): 457–64. doi:10.1002/ana.410270502. PMID 2360787.
  3. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991). “Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment”. Ann. Neurol. 30 (4): 572–80. doi:10.1002/ana.410300410. PMID 1789684.
  4. Selkoe DJ (1989). “Amyloid beta protein precursor and the pathogenesis of Alzheimer’s disease”. Cell. 58 (4): 611–2. PMID 2504495.
  5. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL (1987). “Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus”. Science. 235 (4791): 880–4. PMID 2949367.
  6. Walsh DM, Selkoe DJ (2004). “Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration”. Protein Pept. Lett. 11 (3): 213–28. PMID 15182223.
  7. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010). “Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models”. Cell. 142 (3): 387–97. doi:10.1016/j.cell.2010.06.036. PMID 20655099.
  8. Delacourte A, Flament S, Dibe EM, Hublau P, Sablonnière B, Hémon B, Shérrer V, Défossez A (1990). “Pathological proteins Tau 64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer’s disease. Demonstration with a panel of antibodies against Tau proteins”. Acta Neuropathol. 80 (2): 111–7. PMID 2117840.
  9. Boekhoorn K, Joels M, Lucassen PJ (2006). “Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus”. Neurobiol. Dis. 24 (1): 1–14. doi:10.1016/j.nbd.2006.04.017. PMID 16814555.
  10. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K (September 2003). “The role of alpha-synuclein in Parkinson’s disease: insights from animal models”. Nat. Rev. Neurosci. 4 (9): 727–38. doi:10.1038/nrn1199. PMID 12951565.
  11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (August 1997). “Alpha-synuclein in Lewy bodies”. Nature. 388 (6645): 839–40. doi:10.1038/42166. PMID 9278044.
  12. Calo L, Wegrzynowicz M, Santivañez-Perez J, Grazia Spillantini M (February 2016). “Synaptic failure and α-synuclein”. Mov. Disord. 31 (2): 169–77. doi:10.1002/mds.26479. PMID 26790375.
  13. Lim KL, Zhang CW (2013). “Molecular events underlying Parkinson’s disease – an interwoven tapestry”. Front Neurol. 4: 33. doi:10.3389/fneur.2013.00033. PMC 3619247. PMID 23580245.
  14. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M, Bezard E (June 2013). “Lysosomal impairment in Parkinson’s disease”. Mov. Disord. 28 (6): 725–32. doi:10.1002/mds.25462. PMC 5131721. PMID 23580333.
  15. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, Hashemi M, Owji AA, Łos MJ (January 2014). “Autophagy and apoptosis dysfunction in neurodegenerative disorders”. Prog. Neurobiol. 112: 24–49. doi:10.1016/j.pneurobio.2013.10.004. PMID 24211851.
  16. Przedborski S, Tieu K, Perier C, Vila M (August 2004). “MPTP as a mitochondrial neurotoxic model of Parkinson’s disease”. J. Bioenerg. Biomembr. 36 (4): 375–9. doi:10.1023/B:JOBB.0000041771.66775.d5. PMID 15377875.
  17. Selvaraj S, Sun Y, Watt JA, Wang S, Lei S, Birnbaumer L, Singh BB (April 2012). “Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling”. J. Clin. Invest. 122 (4): 1354–67. doi:10.1172/JCI61332. PMC 3314472. PMID 22446186.
  18. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (June 1989). “Mitochondrial complex I deficiency in Parkinson’s disease”. Lancet. 1 (8649): 1269. PMID 2566813.
  19. Greenamyre JT, Hastings TG (May 2004). “Biomedicine. Parkinson’s–divergent causes, convergent mechanisms”. Science. 304 (5674): 1120–2. doi:10.1126/science.1098966. PMID 15155938.
  20. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (November 2003). “Mechanism of toxicity in rotenone models of Parkinson’s disease”. J. Neurosci. 23 (34): 10756–64. PMID 14645467.
  21. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM (May 2007). “Individual dopaminergic neurons show raised iron levels in Parkinson disease”. Neurology. 68 (21): 1820–5. doi:10.1212/01.wnl.0000262033.01945.9a. PMID 17515544.
  22. Dusek P, Jankovic J, Le W (April 2012). “Iron dysregulation in movement disorders”. Neurobiol. Dis. 46 (1): 1–18. doi:10.1016/j.nbd.2011.12.054. PMID 22266337.
  23. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI (January 2012). “Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export”. Nat. Med. 18 (2): 291–5. doi:10.1038/nm.2613. PMID 22286308.
  24. Hirsch EC, Hunot S (April 2009). “Neuroinflammation in Parkinson’s disease: a target for neuroprotection?”. Lancet Neurol. 8 (4): 382–97. doi:10.1016/S1474-4422(09)70062-6. PMID 19296921.
  25. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (January 2009). “Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease”. J. Clin. Invest. 119 (1): 182–92. doi:10.1172/JCI36470. PMC 2613467. PMID 19104149.
  26. van der Mast, Rose C. (1998). “Pathophysiology of Delirium”. Journal of Geriatric Psychiatry and Neurology. 11 (3): 138–145. doi:10.1177/089198879801100304. ISSN 0891-9887.
  27. Felicetta, James V. (2016). “Effects of illness on thyroid function tests”. Postgraduate Medicine. 85 (8): 213–220. doi:10.1080/00325481.1989.11700751. ISSN 0032-5481.
  28. Trzepacz, Paula T. (1994). “The Neuropathogenesis of Delirium”. Psychosomatics. 35 (4): 374–391. doi:10.1016/S0033-3182(94)71759-X. ISSN 0033-3182.
  29. Hopkins SJ, Rothwell NJ (February 1995). “Cytokines and the nervous system. I: Expression and recognition”. Trends Neurosci. 18 (2): 83–8. PMID 7537419.
  30. Renault, Pierre; Hoofnagle, Jay (2008). “Side Effects of Alpha Interferon”. Seminars in Liver Disease. 9 (04): 273–277. doi:10.1055/s-2008-1040523. ISSN 0272-8087.
  31. Müller, N. (1997). “Die Rolle des Zytokinnetzwerks im ZNS und psychische Störungen”. Der Nervenarzt. 68 (1): 11–20. doi:10.1007/s001150050092. ISSN 0028-2804.
  32. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T (1999). “Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum”. Am. J. Hum. Genet. 65 (3): 664–70. doi:10.1086/302553. PMC 1377972. PMID 10441572.
  33. Tsuang D, Larson EB, Bowen J, McCormick W, Teri L, Nochlin D, Leverenz JB, Peskind ER, Lim A, Raskind MA, Thompson ML, Mirra SS, Gearing M, Schellenberg GD, Kukull W (1999). “The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series”. Arch. Neurol. 56 (12): 1489–95. PMID 10593304.
  34. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC (2004). “Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study”. Arch. Gen. Psychiatry. 61 (5): 518–24. doi:10.1001/archpsyc.61.5.518. PMID 15123497.
  35. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013). “Variant of TREM2 associated with the risk of Alzheimer’s disease”. N. Engl. J. Med. 368 (2): 107–16. doi:10.1056/NEJMoa1211103. PMC 3677583. PMID 23150908.
  36. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG (October 2009). “Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease”. N. Engl. J. Med. 361 (17): 1651–61. doi:10.1056/NEJMoa0901281. PMC 2856322. PMID 19846850.
  37. Klein C, Schlossmacher MG (November 2007). “Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder”. Neurology. 69 (22): 2093–104. doi:10.1212/01.wnl.0000271880.27321.a7. PMID 17761553.
  38. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (March 2002). “A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1”. Ann. Neurol. 51 (3): 296–301. PMID 11891824.
  39. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denèfle P, Wood NW, Agid Y, Brice A (May 2000). “Association between early-onset Parkinson’s disease and mutations in the parkin gene”. N. Engl. J. Med. 342 (21): 1560–7. doi:10.1056/NEJM200005253422103. PMID 10824074.
  40. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (May 2004). “Hereditary early-onset Parkinson’s disease caused by mutations in PINK1”. Science. 304 (5674): 1158–60. doi:10.1126/science.1096284. PMID 15087508.
  41. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P (January 2003). “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism”. Science. 299 (5604): 256–9. doi:10.1126/science.1077209. PMID 12446870.
  42. van Munster, Barbara C.; Aronica, Eleonora; Zwinderman, Aeilko H.; Eikelenboom, Piet; Cunningham, Colm; de Rooij, Sophia E.J.A (2011). “Neuroinflammation in Delirium: A Postmortem Case-Control Study”. Rejuvenation Research. 14 (6): 615–622. doi:10.1089/rej.2011.1185. ISSN 1549-1684.
  43. van Munster, Barbara C.; Aronica, Eleonora; Zwinderman, Aeilko H.; Eikelenboom, Piet; Cunningham, Colm; de Rooij, Sophia E.J.A (2011). “Neuroinflammation in Delirium: A Postmortem Case-Control Study”. Rejuvenation Research. 14 (6): 615–622. doi:10.1089/rej.2011.1185. ISSN 1549-1684.
  44. Ely, Wesley E; Girard, Timothy D.; Shintani, Ayumi K.; Jackson, James C.; Gordon, Sharon M.; Thomason, Jason W. W.; Pun, Brenda T.; Canonico, Angelo E.; Light, Richard W.; Pandharipande, Pratik; Laskowitz, Daniel T. (2007). “Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in critically ill patients*”. Critical Care Medicine. 35 (1): 112–117. doi:10.1097/01.CCM.0000251925.18961.CA. ISSN 0090-3493.
  45. Zhu, Fei; Liu, Jing-Li; Li, Jing-Pin; Xiao, Fang; Zhang, Zhao-Xia; Zhang, Lei (2013). “MicroRNA-124 (miR-124) Regulates Ku70 Expression and is Correlated with Neuronal Death Induced by Ischemia/Reperfusion”. Journal of Molecular Neuroscience. 52 (1): 148–155. doi:10.1007/s12031-013-0155-9. ISSN 0895-8696.
  46. Murakami T, Shoji M, Imai Y, Inoue H, Kawarabayashi T, Matsubara E, Harigaya Y, Sasaki A, Takahashi R, Abe K (March 2004). “Pael-R is accumulated in Lewy bodies of Parkinson’s disease”. Ann. Neurol. 55 (3): 439–42. doi:10.1002/ana.20064. PMID 14991825.
  47. Pan T, Kondo S, Le W, Jankovic J (August 2008). “The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease”. Brain. 131 (Pt 8): 1969–78. doi:10.1093/brain/awm318. PMID 18187492.
  48. Jellinger KA (2000). “Cell death mechanisms in Parkinson’s disease”. J Neural Transm (Vienna). 107 (1): 1–29. doi:10.1007/s007020050001. PMID 10809400.
  49. Tatton WG, Chalmers-Redman R, Brown D, Tatton N (2003). “Apoptosis in Parkinson’s disease: signals for neuronal degradation”. Ann. Neurol. 53 Suppl 3: S61–70, discussion S70–2. doi:10.1002/ana.10489. PMID 12666099.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2] Kiran Singh, M.D. [3]

Overview

Life threatening causes of altered mental status include malignant hypertension, myocardial infarction, rabies and sepsis. Other common causes of altered mental status include alcohol withdrawal, dehydration, electrolyte disturbance and hypoglycemia.

Causes

Life Threatening Causes

Common Causes

Causes by Organ System

Cardiovascular Carotid artery stenosis, congestive heart failure, decreased cardiac output ,disseminated intravascular coagulation, heart attack, hypotension, hypoxemia, malignant hypertension, myocardial infarction, nonbacterial thrombotic endocarditis, pulmonary embolism, rheumatic fever, shock, sleep apnea, stroke, subacute bacterial endocarditis, ventricular arrhythmia
Chemical/Poisoning Atropa belladonna extract, bromide, brown snake poisoning, carbon monoxide poisoning, carbon tetrachloride, carbonyl poisoning, coral snake poisoning, cyanide, daphne poisoning, ethanol, ethylene glycol, gamma hydroxybutyrate, hallucinogens, heroin, hydrocarbon poisoning, hydrogen sulfide, hypomagnesemia, iron compounds, Jimson weed, ketamine, lead, lithium, mandrake, manganese, marijuana, methanol, milk poisoning, nickel, organic solvent, paraldehyde, perazine, phencyclidine poisoning, poison hemlock, psilocybin, snake bite, spider bite,Texas Mescalbean poisoning, thallium sulfate poisoning, toluene, water hemlock poisoning
Dental No underlying causes
Dermatologic Burns, chester porphyria, plague, porphyria
Drug Side Effect Acyclovir, alfentanil, alphaprodine, amantadine, amiloride, aminoglycosides, aminophylline, amitriptyline, amlodipineamobarbital, amphetamine, amphotericin B, analgesics, antiarrhythmics, anticholinergics, antidepressants, antiemetics, antihistamines antimalarials, antipsychotic agents, antispasmodics, apomorphine, aripiprazole, armodafinil, amobarbital, asparaginase, aspirin, atropine, baclofen, barbiturates, benzodiazepines, beta blockers, blinatumomab, bromocriptine, bupivacaine, buprenorphine, butorphanol, cabergoline, camphorated opium tincture, carbamazepine, cephalosporins, chlophedianol, chloroquine, chlorpheniramine, chlorpromazine,cholinesterase inhibitors, cinnarizine, ciprofloxacin, clomethiazole, clonazepam, clonidine, clozapine, cocaine, codeine, corticosteroids, cyclazocine, cyclobenzaprine, cycloserine, deserpidine, desipramine, dexamfetamine, dextromoramide, dezocine, diamorphine, diazepam, digoxin, dihydrocodeine, diphenhydramine, dipipanone, disulfiram, diuretics, domperidone, donepezil, dopamine agonists, dothiepin, doxylamine, drug overdose, drug withdrawal, efavirenz, eszopiclone, ethosuximide, ethotoin, ethylmorphine, fentanyl, fludarabine, fluoroquinolones, gabapentin, general anaesthesia, glutethimide, guanethidine, hallucinogens, histamine-2 receptor blocker, hydromorphone, hydroxyzine, ifosfamide, interferon, interleukin, isoniazid, ketobemidone, L-dopa, lanatoside C, lenalidomide, levetiracetam, levodopa, levomepromazine, levorphanol, lidocaine, linezolid, lithium, loperamide, lorazepam, lysergic acid diethylamide, lysuride, macrolides, marijuana, memantine, meptazinol, mescaline, methadone, methadyl acetate, methcathinone, methyldopa, methyldopate, methylenedioxymethamphetamine, methylphenidate, metronidazole, mirtazapine, monoamine oxidase inhibitors, monomethylhydrazine, morphine, muscle relaxant, mushrooms, nabilone, nalbuphine, nalidixic acid, nelarabine, nitrazepam, nonsteroidal anti-inflammatory drugs, norfloxacin, norpropoxyphene, nortriptyline, noscapine, olanzapine, opiates, opium, oxazepam, oxycodone, oxycontin, oxymorphone, papaveretum, penicillins, pentazocine, perampanel, pergolide, pethidine, phenazocine, phencyclidine, phenelzine, phenobarbital, phenoperidine, phenothiazines, phentermine, phenytoin, pholcodine, piribedil, piritramide, pizotifen, pomalidomide, pramipexole, prednisolone, primidone, prochlorperazine, propoxyphene, propranolol, psychotropics, quetiapine, quinine, quinolones, ramelteon, rasagiline, remifentanil, reserpine, retigabine, rifampin, risperidone, rivastigmine, ropinirole, salicylate, secobarbital, sedative hypnotics, sedatives, selective serotonin reuptake inhibitors, selegiline, skeletal muscle relaxant, st John’s wort, steroid abuse, sufentanil, sulfonamides, thioridazine, tricyclic antidepressants, zaleplon, ziprasidone, zolpidem, zopiclone
Ear Nose Throat Presbyacusis
Endocrine Addisonian crisis, adrenal cortex insufficiency, carcinoid crisis, cushing syndrome, diabetic coma, diabetic hypoglycemia, diabetic ketoacidosis, elevated or depressed adrenal function, elevated or depressed pancreas function, elevated or depressed pituitary function, hyperglycemia, hyperosmolar non-ketotic diabetic coma, hyperosmolar states, hyperthyroidism, hypoglycemia, hypopituitarism, hypothyroidism, myxedema coma, phaeochromocytoma, pituitary apoplexy, thyrotoxicosis
Environmental Acute altitude sickness, decompression sickness, electric shock, heat stroke, hyperthermia, hypothermia, sick building syndrome
Gastroenterologic Acute diverticulitis, appendicitis, carcinoid crisis, cirrhosis of liver, constipation, folate deficiency, hepatic encephalopathy, hepatic failure, mesenteric ischemia, mucormycosis, Reye’s syndrome, rhinocerebral mucormycosis rhinocerebral zygomycosis
Genetic Acute intermittent porphyria, adrenal leukodystrophy, chester porphyria, citrullinemia type 2, coproporphyria hereditary
Hematologic Chester porphyria, disseminated intravascular coagulation, fat emboli, folate deficiency, hypovolemia, internal bleeding, hypercoagulable state, hypereosinophilia, leukostasis, methemoglobinemia, plague, polycythemia, porphyria, prothrombotic state, pulmonary embolism, severe hemorrhage
Iatrogenic Neuroleptic malignant syndrome, serotonin syndrome
Infectious Disease Appendicitis, bacterial meningitis, bartonella infections, brain abscess, brain infection, Brill-Zinsser disease, cat scratch disease , cerebral abscess, cerebral malaria, chest infection, Creutzfeldt-Jakob disease, disseminated intravascular coagulation, epidemic typhus, epidural abscess, human immunodeficiency virus (HIV), infectious mononucleosis, intracranial abscess, intracranial granuloma, legionella infection, listeria, Lyme disease, malaria, mucormycosis, neurocysticercosis,neurosyphilis, plague, postoperative septicemia, pyelonephritis, acute, rabies, recrudescent typhus rhinocerebral mucormycosis, Rickettsiae, sepsis, septic shock, sleeping sickness (East African), sleeping sickness (West African), streptococcal infections, subacute bacterial endocarditis, subdural empyema, surgical wound infection, syphilis, systemic infection, systemic inflammatory response syndrome, typhoid fever, urinary tract infection, vancomycin resistant enterococcal bacteremia, viral hemorrhagic fever
Musculoskeletal/Orthopedic Fat emboli, gangrene
Neurologic Acute altitude sickness, acute disseminated encephalomyelitis, advanced sleep phase disorder, bacterial meningitis, basilar occlusion, bilateral anterior cerebral artery occlusion, bilateral internal carotid occlusion , basal ganglia diseases, brain abscess, brain damage, brain edema, brain infection, brain tumor, brainstem hemorrhage brain stem infarction, central pontine myelinolysis, Cerebral abscess, cerebral hypoxia, cerebral infarction, cerebral malaria, cerebral oedema, cerebral vasculitis, cerebrovascular accident, Creutzfeldt-Jakob disease, decompression sickness, delayed sleep phase syndrome, dementia, dialysis encephalopathy, encephalitis, encephalopathy, epidural abscess, epidural haemorrhage, epidural hematoma, epileptic seizures, extradural hematoma, fat emboli, fungal meningitis, gangrene, head injury, hepatic encephalopathy, hydrocephalus, hyperbaric sickness, hypertensive encephalopathy, intracerebral hemorrhage, intracranial abscess, intracranial granuloma, intracranial space-occupying lesion, Korsakoff’s Syndrome, leukoencephalopathy, Lewy body dementia, supratentorial infarction, meningitis, meningoencephalitis, midline brainstem tumor, multifocal leukoencephalopathy, multiple sclerosis, neurocysticercosis, neurosyphilis, nonconvulsive status epilepticus, pain, panayiotopoulos syndrome, Pick’s disease, pontine hemorrhage, postictal state, postinfectious encephalomyelitis, raised intracranial pressure, reversible posterior leukoencephalopathy syndrome, Reye’s syndrome, sagittal sinus thrombosis, seizure, stroke, subarachnoid haemorrhage, subdural haemorrhage
Nutritional/Metabolic Acute intermittent porphyria, adrenal leukodystrophy, aminoacidemia, Burnett’s syndrome, citrullinemia type 2, Cope’s syndrome, coproporphyria,hereditary, folate deficiency, hyperammonemia, hypercalcaemia, hyperglycemia, hypermagnesemia, hypernatremia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesemia, hyponatraemia, Korsakoff’s Syndrome, lipid storage disorder, niacin deficiencies, niacin deficiency, pellagra,porphobilinogen synthase deficiency, starvation, thiamine (Vitamin B1) deficiency, vitamin B12 deficiency, Wilson’s disease
Obstetric/Gynecologic Eclampsia, hyperoestrogenic states, preeclampsia
Oncologic Brain tumor, carcinoid crisis, leukemic blast cell crisis, midline brainstem tumor, phaeochromocytoma, subependymoma
Ophthalmologic No underlying causes
Overdose/Toxicity Alcohol overdose, drug overdose, heroin overdose, Illegal drug overdose
Psychiatric Advanced sleep phase disorder, alcohol withdrawal, anxiety state, bipolar disorder, brief psychotic disorder, catatonia, chronic fatigue syndrome, delayed sleep phase syndrome, dementia, depression, drug abuse, hysteria, Kleine–Levin syndrome, Korsakoff’s Syndrome, Lewy body dementia, mental health, narcolepsy, neuroleptic malignant syndrome, postoperative stress, psychiatric disorders, schizoaffective disorder,schizophrenia, suicide
Pulmonary Respiratory failure, hypoxemia, hypercarbia, acute altitude sickness, chest infection, fat emboli,hypercapnia, plague, pulmonary embolism, respiratory acidosis, respiratory failure, sleep apnea
Renal/Electrolyte Burnett’s syndrome, Cope’s syndrome, electrolyte disturbance, hypercalcaemia, hypermagnesemia, hypernatremia, hyperphosphatemia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesemia, hyponatraemia, hyperosmolar states, hypoosmolar states, hypophosphatemia , interstitial nephritis, kidney failure, lactic acidosis, membranoproliferative glomerulonephritis, pyelonephritis, acute, renal failure, acute, renal failure, chronic, respiratory acidosis, uremia, dehydration
Rheumatology/Immunology/Allergy Chronic fatigue syndrome, fibromyalgia, vasculitis, rheumatic fever
Sexual No underlying causes
Trauma Electric shock, electrocution, head injury, skull fracture, trauma
Urologic No underlying causes
Miscellaneous Henbane, salvia

Causes in Alphabetical Order

The unnamed parameter 2= is no longer supported. Please see the documentation for {{columns-list}}.
4

References

Template:WikiDoc Sources

Template:WH Template:WS

Differentiating Altered mental status for other Disorders

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Overview

Differential Diagnosis

A lowered level of consciousness indicate a deficit in brain function. Level of consciousness can be lowered when the brain receives insufficient oxygen (as occurs in hypoxia); insufficient blood (as occurs in shock); or has an alteration in the brain’s chemistry.[1] Metabolic disorders such as diabetes mellitus and uremia can alter consciousness. Hypo- or hypernatremia (decreased and elevated levels of sodium, respectively) as well as dehydration can also produce an altered LOC.[2] A pH outside of the range the brain can tolerate will also alter LOC.[3] Exposure to drugs (e.g. alcohol) or toxins may also lower LOC,[1] as may a core temperature that is too high or too low (hyperthermia or hypothermia). Increases in intracranial pressure (the pressure within the skull) can also cause altered LOC. It can result from traumatic brain injury such as concussion. Stroke and intracranial hemorrhage are other causes. Infections of the central nervous system may also be associated with decreased LOC; for example, an altered LOC is the most common symptom of encephalitis.[4] Neoplasms within the intracranial cavity can also affect consciousness, as can epilepsy and post-seizure states.[3] A decreased LOC can also result from a combination of factors. A concussion, which is a mild traumatic brain injury (MTBI) may result in decreased LOC.

Other Illnesses That Can Mimic Delirium, Stupor, and Coma

In patients with altered mental status, the emergency physician must also consider other neurologic diagnoses. In patients who appear unresponsive, locked-in syndrome should be considered and is caused by focal injury to the ventral pons secondary to an infarct, hemorrhage, or trauma. If secondary to an infarct, the distal basilar artery is usually occluded. Multiple sclerosis and central pontine myelinosis can also cause locked-in syndrome. Though the clinical presentation is variable, quadriplegia and anarthria is usually present, but vertical eye gaze and upper eyelid movement are usually retained. Despite having the outward appearance of being unresponsive, patients with locked-in syndrome have normal levels of consciousness and are fully aware of their surroundings. If locked-in syndrome is suspected, then prompt neuroimaging and neurology consultation are warranted. Patients with a suspected thromboembolic cause of locked-in syndrome should immediately go to interventional radiology for intra-arterial thrombolytic therapy, even if the symptoms have being ongoing for more than the traditional 3-hour window. Without emergent intervention, survival and neurological recovery for these patients can be poor.

Non-convulsive status epilepticus (NCSE) should also be considered in patients who have altered mental status, especially if no obvious cause for their mental status changes is found. This diagnosis should strongly be considered if the patient has a seizure history or had a seizure prior to arriving to the ED. One systematic review reported that NCSE occurred in 8% – 30% of patients with altered mental status (mean prevalence = 22%). This systematic review consisted of 5 studies that predominantly enrolled patients in the hospital setting. NCSE is an underrecognized and important form of altered mental status that can only be diagnosed with electroencephalography (EEG). If this cause of altered mental status is considered, then neurology consultation should be obtained promptly; the treatment of NSCE (benzodiazepine and anti-epileptic medications) is significantly different from other causes of altered mental status.

References

  1. 1.0 1.1 Pollak AN, Gupton CL (2002). Emergency Care and Transportation of the Sick and Injured. Boston: Jones and Bartlett. p. 140. ISBN 0-7637-1666-9. Retrieved 2008-07-04.
  2. Johnson AF, Jacobson BH (1998). Medical Speech-language Pathology: A Practitioner’s Guide. Stuttgart: Thieme. p. 142. ISBN 0-86577-688-1. Retrieved 2008-07-04.
  3. 3.0 3.1 Tindall SC (1990). “Level of consciousness”. In Walker HK, Hall WD, Hurst JW. Clinical Methods: The History, Physical, and Laboratory Examinations. Butterworth Publishers. Retrieved 2008-07-04.
  4. Scheld WM, Whitley RJ, Marra CM (2004). Infections of the Central Nervous System. Hagerstown, MD: Lippincott Williams & Wilkins. p. 219. ISBN 0-7817-4327-3. Retrieved 2008-07-04.

Template:WikiDoc Sources

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]


Overview

Epidemiology and Demographics

References

Template:WikiDoc Sources

Template:WH Template:WS

Risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]


Overview

Risk Factors

The etiology of delirium (and other forms of acute brain dysfunction) involves a complex interplay between patient vulnerability (or predisposing) factors and precipitating factors. Patients who are highly vulnerable (e.g. 92 year old with severe dementia, poor functional status, and multiple comorbidities) will require a relatively benign insult to develop delirium. For these patients, a relatively benign insult such as a simple urinary tract infection or small dose of narcotic medication can precipitate delirium. Because elderly patients are more likely to have multiple vulnerability factors, they are more susceptible to becoming delirious compared with their younger counterparts. Nursing home patients are particularly vulnerable. For patients who are less vulnerable (e.g. 67 year old with no dementia, little comorbidity burden, and who is still functionally independent), higher doses of noxious stimuli such as severe sepsis are required to develop delirium. Consequently, when a patient with little or no vulnerability factors presents to the ED with delirium, stupor, or coma, the clinician should have more concern for an underlying life threatening illness. To develop stupor of coma, even higher doses of noxious stimuli are required.

Patient Vulnerability Factors for Acute Brain Dysfunction

A multitude of patient vulnerability factors for delirium have been identified in the hospital literature and can likely be extrapolated to stupor and coma. Dementia is the most consistently observed vulnerability factor for delirium regardless of clinical setting. A dose-response relationship seems to exist; as the severity of dementia worsens, the risk of developing delirium increases. Similarly, low education attainment also increases the patient’s susceptibility to developing delirium. Both dementia and education attainment may be indicative of poor cognitive reserve and reflect the inability of the brain to adequately compensate for any noxious or stressful physiological insult. Other commonly observed vulnerability factors for delirium include poor functional status, advanced age, home psychoactive medication use such as narcotics, benzodiazepines, and medications with anticholinergic properties, history of alcohol abuse, visual impairment, high comorbidity burden, and malnutrition. There are limited data from the ED setting, but one study identified dementia, premorbid functional impairment, and hearing impairment as risk factors for delirium in the ED.14 Another ED study also identified dementia as a risk factor for delirium. They also observed that patients with advanced age, or a past history of cerebrovascular disease and seizure disorder were more likely to be delirious in the ED.

Medication Risk Factors for Delirium

Medications are important vulnerability and precipitating risk factors factor for delirium, because polypharmacy is highly prevalent in the older patient population. Clegg et al. performed a systematic review and observed that benzodiazepines, opioids, dihydropyridines (e.g. nifedpine), and antihistamines may increase the risk for delirium. Of the opioids, meperidine is probably the most deliriogenic. These medications, especially benzodiazepines and opioids, can also induce stupor and coma at higher doses.

Medications with anticholinergic properties are thought to be frequent causes of delirium. There are over 600 medications with anticholinergic properties, and of these, 11% are frequently prescribed to the older patients.80 Some examples of commonly prescribed medications with anticholinergic properties are diphenhydramine, promethazine, hydroxyzine, meclizine, lomotil, and heterocyclic antidepressants (e.g. amitriptyline, nortriptyline, doxepin). In acute stroke patients, Caerio et al. found that that patients on home medications with anticholinergic properties were more susceptible to developing delirium during hospitalization. In 278 older medical patients, Han et al. observed that anticholinergic medications were associated with increased delirium severity. However, the evidence linking medications with anticholinergic properties and delirium is not consistently observed. Agostini et al. observed a trend towards increase risk (relative risk = 2.1, 95%CI: 0.9 – 4.7) of developing delirium in older hospitalized patients when diphenhydramine was used.83 Luukkanen et al. found that older patients who used more than one medication with anticholinergic properties were more likely to have delirium in the unadjusted analysis (27.0% versus 16.7%, p-value = 0.05). However, this relationship became non-significant after adjusting for age, gender, and comorbidity. In 147 hospitalized older patients, Campbell et al. observed that anticholinergic medications were not associated with delirium that developed in the hospital. These discrepant observations may be a result of patient characteristics (stroke versus non-stroke, race, etc.,) or the method in which anticholinergic burden was measured. Despite these discrepant findings, the general consensus among geriatric and psychiatric experts is that medications with anticholinergic properties in older patients should be avoided, especially if safer alternatives exist.

References

Template:WikiDoc Sources

Template:WH Template:WS

Natural History, Complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]


Overview

Natural History, Complications and Prognosis

Delirium, stupor, and coma represent a broad spectrum of acute brain dysfunction and are associated with an impairment of consciousness. There are two interrelated domains of neurologic function that are related to consciousness:

  1. Content
  2. Level (also known as arousal) of consciousness.

The content of consciousness has many components such as orientation, perception, executive function, and memory, and is mediated at the cortical level. The level (or arousal) of consciousness signifies the patient’s wakeful state and reactivity to surrounding stimuli. This is mediated at the ascending reticular activating system located in the brainstem. Traditionally, terms such as lethargic, drowsy, or somnolent have been used to describe level or arousal of consciousness. Because these descriptors can have different meanings for different clinicians, using a structured arousal scale such as the Richmond Agitation Sedation Scale (RASS) may be a more reliable method to describe altered level of consciousness. This scale ranges from -5 (unresponsive to pain and voice) to +4 (extreme combativeness). As the patient’s level of consciousness becomes more disturbed, the concern for an underlying life threatening acute medical illness should similarly increase. Patients with acute brain dysfunction can not only fluctuate between different RASS scores, but can also transition between delirium, stupor, and coma.


Stupor and Coma: Definitions and their Epidemiology in the Emergency Department

Stupor and coma occurs in 5 to 9% of older ED patients and when present, are considered to be medical emergencies that require immediate evaluation. These two forms of acute brain dysfunction occur over a period of hours to days and represent the most severe disruptions in both the level and content of consciousness. Stupor (RASS −4) is a condition of deep sleep or similar behavioral unresponsiveness from which the patient can be aroused only with vigorous and continuous stimulation. Coma (RASS −5) is defined as a state of unresponsiveness in which the patient cannot be aroused with any stimuli.

Delirium: Definitions and its Epidemiology in the Emergency Department

Delirium is an acute disturbance of consciousness (i.e. attention) that is accompanied by an acute loss in cognition that is not better explained by a preexisting dementia. This form of acute brain dysfunction occurs in 8 to 10% of patients of older ED patients. Similar to stupor and coma, delirium occurs over a period of hours and days, and its course tends to wax and wane throughout the day. In contrast to stupor and coma, however, some elements of the level and content of consciousness are maintained in patients with delirium. The degree of impairment in the level of consciousness can be variable, ranging from moderate sleepiness (RASS −3) to extreme combativeness (RASS +4). Patients with delirium also have inattention which is considered a cardinal feature of delirium. The impairment of content of consciousness is similarly variable and leads to an acute loss in cognition. Examples of such impairments observed in delirious patients are disorganized thought, perceptual disturbances, and disorientation.

The Psychomotor Subtypes of Delirium

Delirium can be further classified into three psychomotor subtypes: hypoactive, hyperactive, and mixed. Hypoactive (RASS < 0) delirium is described as “quiet” delirium and is characterized by psychomotor retardation; delirious patients with this subtype can appear drowsy, somnolent, or even lethargic. Because the clinical presentation can be very subtle, hypoactive delirium is frequently undetected by health care providers,21 and is often attributed to other etiologies such as depression or fatigue. To the contrary, patients with hyperactive delirium (RASS > 0) have increased psychomotor activity and may appear restless, anxious, agitated, or combative. Hyperactive delirium is more easily recognized by health care providers. Mixed-type delirium exhibits fluctuating levels of psychomotor activity; the patient can exhibit hypoactive symptomatology at one moment and hyperactive symptomatology several hours or even seconds later. Hypoactive delirium and mixed-type delirium appear to be the predominant subtypes in older patients regardless of the clinical setting. In the ED specifically, hyperactive delirium is the least common subtype.

It is hypothesized that each psychomotor subtype has different underlying pathophysiological mechanisms. Though the mechanisms are unclear, it is hypothesized that each delirium subtypes has differential neurotransmitter activity (cholinergic, dopamine, serotonin, and gamma-aminobutyric acid). Each psychomotor subtype may also be cause by different etiologies. Delirium caused by an infection or metabolic derangement is more likely to be the hypoactive subtype, whereas delirium caused by alcohol or benzodiazepine withdrawal is more likely to be the hyperactive subtype. The psychomotor subtypes of delirium may also have a differential effect on clinical course and outcomes. In 225 older patients admitted to a post acute care facility, Kiely at al. observed that patients with hypoactive delirium had the highest 1-year mortality rate compared with the other subtypes.

Delirium versus Dementia

Delirium is distinct from dementia, yet many clinicians use these terms interchangeably. It is important to note, however, that dementia is an important predisposing factor to delirium, and patients can have both conditions concurrently. As previously mentioned, the loss of cognition observed in delirium tends to occur rapidly, and its course tends to fluctuate throughout the day. The loss of cognition observed in dementia is usually gradual (over months to years), and its course tends to be stable. Patients with delirium also have inattention, which is considered the cardinal feature of delirium where as attention is usually preserved in patients with dementia. Altered level of consciousness, disorganized thinking, sleep-wake cycle disturbances, and perceptual disturbances are also commonly observed in delirium, whereas these characteristics are typically absent in dementia.

There are instances when the clinical features of delirium and dementia overlap, making them difficult to distinguish from each other. This is especially the case in patients with end-stage dementia, where they can exhibit symptoms of inattention, altered level of consciousness, disorganized thinking, sleep-wake cycle disturbances, and perceptual disturbances in the absence of delirium.34 When patients with end-stage dementia develop delirium, an acute change in mental status is still observed, and any pre-existing abnormalities in cognition and level of consciousness will likely worsen. For this reason, diagnosing delirium can be extremely challenging in patients with severe dementia and establishing their baseline mental status is critical to the diagnosis.

Delirium is classically thought of as reversible and is usually precipitated by an underlying medical illness. However, there are also a proportion of patients whose delirium is not transient, and their symptoms can persist for months or even years. Dementia is thought of as irreversible and not secondary to an underlying medical illness. However, there are circumstances in which dementia may be reversible. Hypothyroidism, normal pressure hydrocephalus, vitamin B12 deficiency, and depression are examples of illnesses that can cause reversible dementia or a dementia-like illness (pseudodementia). One meta-analysis comprised of 39 articles reported that 9% of dementia were potentially reversible, but only 0.6% of the dementia cases showed any improvement in cognition after the reversible cause was addressed.

Dementia with Lewy bodies is the second most common type of dementia (after Alzheimer’s) and deserves special mention because it can be very challenging to distinguish from delirium. Similar to delirium, the loss of cognition observed in dementia with Lewy bodies can be rapid, and it can fluctuate over several hours or days. Perceptual disturbances are also commonly observed in dementia with Lewy bodies. Patients with dementia with Lewy bodies, however, have Parkinsonian motor symptoms such as cog wheeling, shuffling gait, stiff movements, and reduced arm-swing during walking; these motor symptoms are usually absent in patients with delirium. Differentiating between dementia with Lewy bodies and delirium can be difficult in the ED and may require a detailed evaluation by a neurologist or psychiatrist.


References

Template:WikiDoc Sources

Template:WH Template:WS

Diagnosis

Diagnosis

Diagnostic Criteria, History and Symptoms, Physical Examination, Laboratory Findings, CT, MRI, Other Diagnostic Studies

Treatment

Treatment

Medical Therapy, Primary Prevention, Secondary Prevention, Cost-Effectiveness of Therapy, Future or Investigational Therapies

Related Chapters
References

References

Template:WikiDoc Sources

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH